Keywords: Ariad, GTx, Ridaforolimus, Toremifene, Metastataic sarcoma, Prostate cancer

Ariad and GTx both see their share price plunge, each after updating on cancer drug clinical trials

Article | 27 May 2010

Print This

Ariad Pharmaceutical’s shares fell 8.7% to $3.58 on the news on May 25 that the independent Data Monitoring Committee of the Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in